Information Provided By:
Fly News Breaks for January 31, 2020
ITCI
Jan 31, 2020 | 05:25 EDT
JPMorgan analyst Jessica Fye downgraded Intra-Cellular Therapies to Neutral from Overweight with a $26 price target.
News For ITCI From the Last 2 Days
There are no results for your query ITCI